Dupilumab
- PDF / 169,394 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 173 Views
1
Dupilumab Conjunctivitis and injection site reaction: 2 case reports In a retrospective study (study period June 2018–December 2018) of 22 adult patients, 2 patients [ages and sexes not stated] were described, who developed conjunctivitis or injection site reaction during treatment with dupilumab for atopic dermatitis. The patients were administered a loading dose of dupilumab 600mg and after 2 weeks, SC dupilumab 300mg injection every 2 weeks. Subsequently, one patient developed conjunctivitis and was treated with unspecified antihistamine eye drops for 6 months, and one patient developed mild injection site reaction during the treatment [time to reactions onsets and outcomes not stated]. Author comment: "With regard to the safety of dupilumab, conjunctivitis was observed. . .One patient required the continued use of antihistamine eye drops 6 months after starting dupilumab. . .We observed a mild injection-site reaction in one patient". Uchida H, et al. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. British Journal of Dermatology 181: 1083-1085, No. 5, Nov 2019. Available from: URL: 803438470 http://doi.org/10.1111/bjd.18163 - Japan
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
